Table 2.

Relationship between FAM19A4 methylation and hrHPV genotyping in hrHPV-positive samples

	HPV genotype	Median Methylation	Methylation Rates	U	P
		Scores($\mathrm{P}\frac{1}{4}-\mathrm{P}\frac{3}{4}$)	(%)
All samples	HPV16/18	32.88(2.91–5129.12)	68.81(75/109)	3268.50	3.783 × 10–8*
	12 other hrHPV a	2.05(0.22–12.10)	30.19(32/106)
Cervical cancer	HPV16/18	141.42(60.63–363.07)	93.88(46/49)	289.50	0.935**
	12 other hrHPV	141.34(30.84–842.89)	91.67(11/12)
HSIL	HPV16/18	14.65(1.67–56.09)	64.29(18/28)	305.00	0.107**
	12 other hrHPV	4.35(0.36–36.85)	48.28(14/29)
LSIL	HPV16/18	3.20(0.90–21.98)	40.00(4/10)	91.00	0.574**
	12 other hrHPV	1.67(1.20–18.35)	33.33(7/21)
No CIN	HPV16/18	1.83(0.50 × 10−2-24.21)	31.82(7/22)	347.00	0.062**
	12 other hrHPV	0.66(0.19 × 10−2-2.13)	0.00(0/44)

^a12 other hrHPV refer to HPV31, 33, 35, 39, 45 51, 52, 56, 58, 59, 66 and 68 infection

*P<0.05,Mann-Whitney U Test, methylation scores were used to calculate the statistical difference

**P>0.05,Mann-Whitney U Test, methylation scores were used to calculate the statistical difference